- Abstract:
-
OBJECTIVES: To evaluate the efficacy and safety of an oral phosphodiesterase 4 inhibitor, apremilast, in treatment of ankylosing spondylitis (AS) by monitoring symptoms and signs in a pilot study including exploratory investigation of effects of PDE4 inhibition on blood biomarkers of bone biology. METHODS: In this double-blind, placebo-controlled, single-centre, Phase II study, patients with symptomatic AS with active disease on MRI were randomised to apremilast 30 mg BID or placebo over 12 ...
Expand abstract - Journal:
- Annals of the rheumatic diseases
- Volume:
- 72
- Issue:
- 9
- Pages:
- 1475-1480
- Publication date:
- 2013-09-05
- DOI:
- EISSN:
-
1468-2060
- ISSN:
-
0003-4967
- URN:
-
uuid:209c3d39-d3fc-4fd8-b7ab-8ce1852b764b
- Source identifiers:
-
352521
- Local pid:
- pubs:352521
- Language:
- English
- Keywords:
- Copyright date:
- 2013
Journal article
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis.
Actions
Authors
Bibliographic Details
Item Description
Terms of use
Metrics
Altmetrics
Dimensions
If you are the owner of this record, you can report an update to it here: Report update to this record